From: europeanpharmaceuticalreview.com The radionuclide treatment combines radioactive iodine therapy with single-domain antibodies to target the HER2 antigen. A Phase I trial has found that radionuclide treatment may offer new therapeutic options for human epidermal growth factor receptor type 2 (HER2)-positive breast cancer. The treatment combines radioactive iodine therapy with single-domain antibodies that target the HER2 antigen to destroy cancer cells. …
IL13Ra2 revealed as target against breast cancer-related brain metastasis
From: drugtargetreview.com A new study conducted by the University of Colorado, US, has looked specifically at the role of interleukin 13 receptor alpha 2 (IL13Ra2), a protein that is found in increased rates in cancer cells that metastasise to other locations in the body – particularly the brain and lungs. The team used experimental HER2 breast-brain metastases models both in …
Value-Based Decision-Making in Metastatic Breast Cancer
From: managedhealthcareexecutive.com In this Managed Healthcare Executive® KCast, Ian Krop, M.D., Ph.D., oncologist and associate professor of medicine at Dana-Farber Cancer Institute in Boston, and Debra Patt, M.D., Ph.D., MBA, executive vice president at Texas Oncology in Austin, provide key insights into the value-based care model for patients with HER2-positive metastatic breast cancer (mBC). This article summarizes the highlights of …
HER2+ Breast Cancer: Key Takeaways From HER2CLIMB
By: Giuseppe Curigliano, MD, PhD From: onclive.com An overview of the latest data demonstrated by the HER2CLIMB study evaluating the efficacy and safety of tucatinib in combination with capecitabine and trastuzumab for patients with relapsed/refractory metastatic HER2-positive breast cancer. Giuseppe Curigliano, MD, PhD: Tucatinib is a highly selective HER2 [human epidermal growth factor receptor 2]–directed tyrosine kinase inhibitor. The specificity …
Samsung Bioepis Announces Five-year Follow-up Results for ONTRUZANT® (trastuzumab) in Early or Locally Advanced HER2 Positive Breast Cancer
Source: Samsung Bioepis From: globenewswire.com Five-year follow-up results show comparable cardiac safety profile and long-term efficacy between biosimilar ONTRUZANT® (trastuzumab) and reference medicine HERCEPTIN® i (trastuzumab) in early or locally advanced HER2 positive breast cancer The longest monitoring data of patients treated with a trastuzumab biosimilar for HER2-positive early or locally advanced breast cancer Results presented at the European Society …
MacroGenics Announces Final Overall Survival Results from SOPHIA Study of MARGENZA™ in Patients with HER2-Positive Metastatic Breast Cancer
Source: MacroGenics From: pipelinereview.com Final overall survival (OS) analysis did not demonstrate a statistically significant advantage for MARGENZA over trastuzumab OS was greater with MARGENZA plus chemotherapy in exploratory subgroups of patients carrying a CD16A 158F allele compared to trastuzumab plus chemotherapy arm, while the OS for trastuzumab plus chemotherapy was greater than MARGENZA plus chemotherapy for the small exploratory …
New approach eradicates breast cancer in mice
By: Diana Yates From: news.illinois.edu A new approach to treating breast cancer kills 95-100% of cancer cells in mouse models of human estrogen-receptor-positive breast cancers and their metastases in bone, brain, liver and lungs. The newly developed drug, called ErSO, quickly shrinks even large tumors to undetectable levels. Led by scientists at the University of Illinois Urbana-Champaign, the research team …
Frontline Treatment Standards for HER2+ mBC
By: Briana Contreras, Debra Patt, MD, PhD, MBA From: managedhealthcareexecutive.com Debra Patt, MD, PhD, MBA, describes the frontline standards of care and the factors involved in deciding on a treatment for human epidermal growth factor receptor 2-positive metastatic breast cancer. Briana Contreras: Hello, everyone, and welcome to this Managed Healthcare Executive® program titled “Value-Based Decision-Making in Metastatic Breast Cancer.” My …
Clinical Challenge: HER2-Positive Breast Cancer in Older Women
By: Leah Lawrence From: medpagetoday.com The challenge may have more to do with the assessment of the patient’s overall health The median age at breast cancer diagnosis is 63, with about 20% of new cases occurring in women older than 75. HER2-positive breast cancer is less common in older women compared with younger women, but still occurs in about 10% …
Tumor marker may help overcome endocrine treatment-resistant breast cancer
Source: Sanford Burnham Prebys Medical Discovery Institute From: eurekalert.org Testing may identify patients who benefit from early HER2 targeted therapy A study led by scientists at Sanford Burnham Prebys Medical Discovery Institute has identified a tumor marker that may be used to predict which breast cancer patients will experience resistance to endocrine therapy. The research offers a new approach to …